메뉴 건너뛰기




Volumn 45, Issue 3, 2013, Pages 236-241

Update on rilpivirine: A new potent non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV replication

Author keywords

HIV; NNRTI; Resistance; Rilpivirine; Treatment

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ANTACID AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; CHOLESTEROL; CREATININE; DAPSONE; DEXAMETHASONE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; HISTAMINE H2 RECEPTOR ANTAGONIST; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; PYRROLE DERIVATIVE; RIFAMYCIN; RILPIVIRINE; TENOFOVIR DISOPROXIL; TRIACYLGLYCEROL; UNINDEXED DRUG; ZIDOVUDINE;

EID: 84876149309     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2012.732704     Document Type: Review
Times cited : (11)

References (20)
  • 1
    • 84862777419 scopus 로고    scopus 로고
    • Efficacy and safety of rilpi- virine (TMC278) versus efavirenz at 48 weeks in treatment-naïve, HIV- 1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials
    • ECHO Study Group; THRIVE Study Group
    • Cohen, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, et al.; ECHO Study Group; THRIVE Study Group. Efficacy and safety of rilpi- virine (TMC278) versus efavirenz at 48 weeks in treatment-naïve, HIV- 1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr. 2012;60:33-42.
    • (2012) J Acquir Immune Defic Syndr , vol.60 , pp. 33-42
    • Cohen1    Molina, J.M.2    Cahn, P.3    Clotet, B.4    Fourie, J.5    Grinsztejn, B.6
  • 2
    • 75749118495 scopus 로고    scopus 로고
    • TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1
    • Azijn H, Tirry I, Vingerhoets J, de Béthune MP, Kraus G, Boven K, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother. 2010; 54 : 718-27.
    • (2010) Antimicrob Agents Chemother , vol.54 , pp. 718-727
    • Azijn, H.1    Tirry, I.2    Vingerhoets, J.3    De Béthune, M.P.4    Kraus, G.5    Boven, K.6
  • 3
    • 79960381844 scopus 로고    scopus 로고
    • ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial
    • Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, et al.; ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378:238-46.
    • (2011) Lancet , vol.378 , pp. 238-246
    • Molina, J.M.1    Cahn, P.2    Grinsztejn, B.3    Lazzarin, A.4    Mills, A.5    Saag, M.6
  • 4
    • 79960358849 scopus 로고    scopus 로고
    • THRIVE study group. Rilpivirine versus efa- virenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naïve adults infected with HIV-1 (THRIVE): A phase 3, randomized, non-inferiority trial
    • Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, et al.; THRIVE study group. Rilpivirine versus efa- virenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naïve adults infected with HIV-1 (THRIVE): a phase 3, randomized, non-inferiority trial. Lancet. 2011;378:229-37.
    • (2011) Lancet , vol.378 , pp. 229-237
    • Cohen, C.J.1    Andrade-Villanueva, J.2    Clotet, B.3    Fourie, J.4    Johnson, M.A.5    Ruxrungtham, K.6
  • 5
    • 84871651718 scopus 로고    scopus 로고
    • Pooled week 96 efficiency, resistance and safety results from the double-blind, randomised, phase III trials comparing rilpivirine (RPV) versus efavirenz (EFV) in treatment-naive, HIV-1 infected adults
    • Rome, Italy, 17-20 July 2011, Abstract no. TULBPE032
    • Cohen CJ, Molina JM, Cassetti I, Chetchotisakd P, Lazzarin A, Rhame F, et al. Pooled week 96 efficiency, resistance and safety results from the double-blind, randomised, phase III trials comparing rilpivirine (RPV) versus efavirenz (EFV) in treatment-naive, HIV-1 infected adults. Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, 17-20 July 2011, Abstract no. TULBPE032.
    • Conference on HIV Pathogenesis, Treatment and Prevention
    • Cohen, C.J.1    Molina, J.M.2    Cassetti, I.3    Chetchotisakd, P.4    Lazzarin, A.5    Rhame, F.6
  • 6
    • 84863190048 scopus 로고    scopus 로고
    • Effect of gender and race on the week 48 findings in treatment- naïve, HIV-1- infected patients enrolled in the randomized, phase III trials ECHO and THRIVE
    • Hodder S, Arasteh K, De Wet J, Gathe J, Gold J, Kumar P, et al. Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1- infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. 2012;13:406-15.
    • (2012) HIV Med , vol.13 , pp. 406-415
    • Hodder, S.1    Arasteh, K.2    De Wet, J.3    Gathe, J.4    Gold, J.5    Kumar, P.6
  • 7
    • 84873933904 scopus 로고    scopus 로고
    • Switching from efavirenz-emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) single table regimen (STR) to emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) STR in virologically suppressed, HIV-1 infected subjects
    • Chicago, IL, 17-20 September 2011. Poster H2-794c
    • Mills A, Cohen C, Dejesus E, Rashbaum B, Brinson C, Yale K, et al. Switching from efavirenz-emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) single table regimen (STR) to emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) STR in virologically suppressed, HIV-1 infected subjects. Presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, 17-20 September 2011. Poster H2-794c.
    • 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
    • Mills, A.1    Cohen, C.2    Dejesus, E.3    Rashbaum, B.4    Brinson, C.5    Yale, K.6
  • 9
    • 84864505008 scopus 로고    scopus 로고
    • Efficacy and safety of rilpivirine in treatment-naive, HIV- 1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials
    • Nelson M, Amaya G, Clumeck N, Arns da Cunha C, Jayaweera D, Junod P, et al. Efficacy and safety of rilpivirine in treatment-naive, HIV- 1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. J Antimicrob Chemother. 2012;67:2020-8.
    • (2012) J Antimicrob Chemother , vol.67 , pp. 2020-2028
    • Nelson, M.1    Amaya, G.2    Clumeck, N.3    Arns Da Cunha, C.4    Jayaweera, D.5    Junod, P.6
  • 10
    • 73649148381 scopus 로고    scopus 로고
    • TMC278-C204 Study Group. Efficacy and safety of TMC278 in antiretroviral-naïve HIV-1 patients: Week 96 results of a phase IIb randomized trial
    • Pozniak AL, Morales-Ramirez J, Katabira E, Steyn D, Lupo SH, Santos- coy M, et al.; TMC278-C204 Study Group. Efficacy and safety of TMC278 in antiretroviral-naïve HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS. 2010;24:55-65.
    • (2010) AIDS , vol.24 , pp. 55-65
    • Pozniak, A.L.1    Morales-Ramirez, J.2    Katabira, E.3    Steyn, D.4    Lupo, S.H.5    Santoscoy, M.6
  • 11
    • 84860455337 scopus 로고    scopus 로고
    • Longterm efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: Week 192 results from a phase IIb randomized trial
    • on behalf of the TMC278-C204 Study Group
    • Wilkin A, Pozniak AL, Morales-Ramirez J, Lupo SH, Santoscoy M, Grinsztejn B, et al.; on behalf of the TMC278-C204 Study Group. Longterm efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. AIDS Res Hum Retroviruses. 2012 ï 28 : 437-46.
    • (2012) AIDS Res Hum Retroviruses , vol.28 , pp. 437-446
    • Wilkin, A.1    Pozniak, A.L.2    Morales-Ramirez, J.3    Lupo, S.H.4    Santoscoy, M.5    Grinsztejn, B.6
  • 13
    • 83655163698 scopus 로고    scopus 로고
    • Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the Phase 3 ECHO and THRIVE studies: 48-week analysis
    • Rimsky L, Vingerhoets J, Van Eygen V, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the Phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr. 2012;59:39-46.
    • (2012) J Acquir Immune Defic Syndr , vol.59 , pp. 39-46
    • Rimsky, L.1    Vingerhoets, J.2    Van Eygen, V.3
  • 14
    • 78751693611 scopus 로고    scopus 로고
    • Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase on susceptibility to etravirine in B and non-B HIV-1 subtypes
    • Asahchop EL, Oliveira M, Wainberg MA, Brenner BG, Moisi D, Toni T, et al. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase on susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrob Agents Chemother. 2011;55:600-7.
    • (2011) Antimicrob Agents Chemother , vol.55 , pp. 600-607
    • Asahchop, E.L.1    Oliveira, M.2    Wainberg, M.A.3    Brenner, B.G.4    Moisi, D.5    Toni, T.6
  • 15
    • 0036822850 scopus 로고    scopus 로고
    • Might the M184V substitution in HIV-1 RT confer clinical benefit?
    • Petrella M, Wainberg MA. Might the M184V substitution in HIV-1 RT confer clinical benefit? AIDS Rev. 2002;4:224-32. (Pubitemid 36104233)
    • (2002) AIDS Reviews , vol.4 , Issue.4 , pp. 224-232
    • Petrella, M.1    Wainberg, M.A.2
  • 16
    • 80055119045 scopus 로고    scopus 로고
    • Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme proces- sivity associated with the M184I/V mutations
    • Xu HT, Asahchop EL, Oliveira M, Quashie PK, Quan Y, Brenner BG, et al. Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme proces- sivity associated with the M184I/V mutations. J Virol. 2011;85: 11300-8.
    • (2011) J Virol , vol.85 , pp. 11300-11308
    • Xu, H.T.1    Asahchop, E.L.2    Oliveira, M.3    Quashie, P.K.4    Quan, Y.5    Brenner, B.G.6
  • 17
    • 80055103177 scopus 로고    scopus 로고
    • Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: Effects on fitness and RT activity of human immunodeficiency virus type 1
    • Hu Z, Kuritzkes DR. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. J Virol. 2011;85:11309-14.
    • (2011) J Virol , vol.85 , pp. 11309-11314
    • Hu, Z.1    Kuritzkes, D.R.2
  • 18
    • 83655201316 scopus 로고    scopus 로고
    • Thie HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness
    • Kulkarni R, Babaoglu K, Lansdon EB, Rimsky L, Van Eygen V, Picchio G, et al. Thie HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness. J Acquir Immune Defic Syndr. 2012;59:47-54.
    • (2012) J Acquir Immune Defic Syndr , vol.59 , pp. 47-54
    • Kulkarni, R.1    Babaoglu, K.2    Lansdon, E.B.3    Rimsky, L.4    Van Eygen, V.5    Picchio, G.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.